Clinical Trial Update: A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immune response and safety of the RmenB + OMV NZ meningitis vaccine in primed healthy participants aged 10-20 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis

Drugs mentioned

• RmenB + OMV NZ meningitis vaccine (RmenB + OMV NZ)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningitis | Phase 3 | Status: COMPLETED